Recursion Pharmaceuticals . Quarterly Balance Sheets Chart
Quarterly
|
Annual
Recursion Pharmaceuticals . Quarterly Balance Sheets Table
Quarterly
|
Annual
| Unit: USD | 2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| assets | ||||||||||||||
| current assets | ||||||||||||||
| cash and cash equivalents | 525,110,000 | 500,453,000 | 427,647,000 | 474,341,000 | 296,326,000 | 387,322,000 | 405,870,000 | 473,145,000 | 454,646,000 | 453,875,000 | 507,891,000 | 394,721,000 | 632,738,000 | 214,088,000 |
| restricted cash | 3,106,000 | 3,075,000 | 1,555,000 | 1,783,000 | 3,195,000 | 2,256,000 | 3,325,000 | 1,311,000 | 2,090,000 | 1,901,000 | 1,521,000 | 10,233,000 | 10,232,000 | 5,042,000 |
| other receivables | 21,606,000 | 46,124,000 | 2,255,000 | 2,526,000 | 2,599,000 | 3,164,000 | 3,051,000 | 2,057,000 | 11,635,000 | 11,659,000 | 11,363,000 | 2,248,000 | ||
| prepaid data assets | 2,470,000 | |||||||||||||
| other current assets | 37,338,000 | 32,023,000 | 42,715,000 | 43,725,000 | 41,495,000 | 17,780,000 | 18,774,000 | 15,612,000 | 13,247,000 | 16,979,000 | 15,432,000 | 9,445,000 | 4,616,000 | 2,621,000 |
| total current assets | 587,160,000 | 584,145,000 | 474,172,000 | 522,375,000 | 343,615,000 | 410,522,000 | 431,020,000 | 492,125,000 | 481,618,000 | 545,996,000 | 619,455,000 | 600,870,000 | 647,635,000 | 221,822,000 |
| restricted cash, non-current | 5,629,000 | 5,629,000 | 6,629,000 | 6,629,000 | 6,629,000 | 7,629,000 | 7,629,000 | 7,920,000 | 8,154,000 | 8,334,000 | 8,713,000 | |||
| property and equipment | 120,038,000 | 126,834,000 | 84,410,000 | 83,633,000 | 86,716,000 | 86,248,000 | 89,768,000 | 90,004,000 | 85,777,000 | 81,508,000 | 70,704,000 | 55,439,000 | 48,549,000 | 44,642,000 |
| operating lease right-of-use assets | 50,324,000 | 53,186,000 | 47,882,000 | 44,088,000 | 35,501,000 | 34,062,000 | 34,899,000 | 35,116,000 | 33,726,000 | 34,643,000 | 33,301,000 | |||
| financing lease right-of-use assets | 23,242,000 | 24,757,000 | 26,897,000 | 28,562,000 | ||||||||||
| intangible assets | 341,319,000 | 335,790,000 | 34,093,000 | 38,210,000 | 33,076,000 | 39,459,000 | 42,757,000 | 1,318,000 | 1,457,000 | 1,233,000 | 1,309,000 | 2,262,000 | 2,338,000 | 2,414,000 |
| goodwill | 164,270,000 | 158,112,000 | 52,056,000 | 52,056,000 | 52,056,000 | 52,750,000 | 60,516,000 | 801,000 | 801,000 | 801,000 | 801,000 | |||
| deferred tax assets | 957,000 | 2,003,000 | ||||||||||||
| other assets, non-current | 9,416,000 | 14,778,000 | 360,000 | 308,000 | 254,000 | 155,000 | 110,000 | 82,000 | ||||||
| total assets | 1,302,355,000 | 1,305,234,000 | 726,499,000 | 775,861,000 | 557,847,000 | 630,825,000 | 666,699,000 | 627,366,000 | 611,533,000 | 672,515,000 | 734,319,000 | 658,606,000 | 698,590,000 | 271,943,000 |
| liabilities and stockholders’ equity | ||||||||||||||
| current liabilities | ||||||||||||||
| accounts payable | 19,314,000 | 25,086,000 | 2,260,000 | 3,762,000 | 5,115,000 | 4,265,000 | 2,086,000 | 4,247,000 | 3,890,000 | 3,176,000 | 4,162,000 | 6,326,000 | 3,196,000 | 3,125,000 |
| accrued expenses and other liabilities | 64,280,000 | 56,804,000 | 40,597,000 | 33,401,000 | 26,070,000 | 39,806,000 | 32,873,000 | 25,041,000 | 26,757,000 | 24,361,000 | 23,118,000 | 25,113,000 | 12,710,000 | 11,085,000 |
| accrued data liability | 20,258,000 | |||||||||||||
| unearned revenue | 39,690,000 | 39,651,000 | 49,579,000 | 32,204,000 | 36,618,000 | 43,997,000 | 73,105,000 | 57,761,000 | 46,753,000 | 63,781,000 | 54,247,000 | |||
| operating lease liabilities | 11,732,000 | 11,853,000 | 8,233,000 | 8,607,000 | 6,062,000 | 5,355,000 | 5,219,000 | 4,440,000 | 5,541,000 | 5,242,000 | 4,086,000 | |||
| notes payable and financing lease liabilities | 8,752,000 | 8,587,000 | 8,219,000 | 8,109,000 | ||||||||||
| total current liabilities | 164,026,000 | 141,981,000 | 108,888,000 | 86,083,000 | 73,920,000 | 94,118,000 | 113,959,000 | 92,150,000 | 83,036,000 | 96,653,000 | 85,705,000 | 42,943,000 | 29,540,000 | 26,854,000 |
| unearned revenue, non-current | 126,243,000 | 129,609,000 | 15,712,000 | 29,169,000 | 37,391,000 | 51,383,000 | 32,436,000 | 57,091,000 | 93,909,000 | 89,934,000 | 107,121,000 | |||
| operating lease liabilities, non-current | 53,395,000 | 56,024,000 | 53,663,000 | 50,239,000 | 43,786,000 | 44,300,000 | 45,850,000 | 46,771,000 | 45,993,000 | 47,763,000 | 47,317,000 | |||
| notes payable and financing lease liabilities, non-current | 14,196,000 | 16,446,000 | 20,510,000 | 22,921,000 | ||||||||||
| deferred tax liabilities | 23,784,000 | 22,437,000 | 168,000 | 528,000 | 1,931,000 | 4,336,000 | ||||||||
| other liabilities, non-current | 1,565,000 | 4,790,000 | 2,999,000 | 3,000,000 | ||||||||||
| total liabilities | 383,209,000 | 371,287,000 | 201,940,000 | 191,412,000 | 156,696,000 | 192,858,000 | 197,736,000 | 197,191,000 | 223,499,000 | 234,936,000 | 240,753,000 | 59,574,000 | 55,876,000 | 56,662,000 |
| commitments and contingencies | ||||||||||||||
| stockholders’ equity | ||||||||||||||
| common stock | 4,000 | 4,000 | 3,000 | 3,000 | 2,000 | 2,000 | 2,000 | 2,000 | 2,000 | 2,000 | 2,000 | |||
| additional paid-in capital | 2,681,111,000 | 2,553,492,000 | 1,776,933,000 | 1,740,981,000 | 1,460,144,000 | 1,312,591,000 | 1,250,570,000 | 1,135,056,000 | 970,096,000 | 959,393,000 | 949,932,000 | 934,175,000 | 930,431,000 | 11,287,000 |
| accumulated deficit | -1,805,589,000 | -1,633,694,000 | -1,252,377,000 | -1,156,535,000 | -1,058,995,000 | -874,626,000 | -781,609,000 | -704,883,000 | -582,064,000 | -521,619,000 | -456,059,000 | -335,147,000 | -287,719,000 | -244,318,000 |
| accumulated other comprehensive income | 43,620,000 | 14,145,000 | 2,000 | |||||||||||
| total stockholders’ equity | 919,146,000 | 933,947,000 | 524,559,000 | 584,449,000 | 401,151,000 | 437,967,000 | 468,963,000 | 430,175,000 | 388,034,000 | 437,579,000 | 493,566,000 | 599,032,000 | 642,714,000 | |
| total liabilities and stockholders’ equity | 1,302,355,000 | 1,305,234,000 | 726,499,000 | 775,861,000 | 557,847,000 | 630,825,000 | 666,699,000 | 627,366,000 | 611,533,000 | 672,515,000 | 734,319,000 | |||
| notes payable | 55,000 | 695,000 | 676,000 | 661,000 | 95,000 | 93,000 | 92,000 | |||||||
| notes payable, non-current | 1,071,000 | 1,126,000 | 1,155,000 | 1,179,000 | 561,000 | 586,000 | 610,000 | |||||||
| accounts receivable | 21,000 | 34,000 | 34,000 | 49,000 | 71,000 | |||||||||
| investments | 61,561,000 | 83,214,000 | 184,189,000 | |||||||||||
| other non-current assets | 36,000 | 35,000 | 68,000 | 3,065,000 | ||||||||||
| lease incentive obligation | ||||||||||||||
| deferred rent | 3,348,000 | 2,819,000 | 2,750,000 | |||||||||||
| lease incentive obligation, non-current | ||||||||||||||
| accumulated other comprehensive loss | -197,000 | -309,000 | ||||||||||||
| liabilities, convertible preferred stock and stockholders’ equity | ||||||||||||||
| current portion of unearned revenue | 10,000,000 | 10,000,000 | 10,000,000 | |||||||||||
| current portion of notes payable | 88,000 | 3,135,000 | 2,145,000 | |||||||||||
| current portion of lease incentive obligation | 1,416,000 | 499,000 | 499,000 | |||||||||||
| unearned revenue, net of current portion | 9,167,000 | 11,667,000 | 14,167,000 | |||||||||||
| notes payable, net of current portion | 656,000 | 9,423,000 | 10,339,000 | |||||||||||
| lease incentive obligation, net of current portion | 3,460,000 | 2,427,000 | 2,552,000 | |||||||||||
| convertible preferred stock (series a, a-1, b, c and d), 0.00001 par value; 200,000,000 and 121,434,713 shares authorized as of september 30, 2021 and december 31, 2020, respectively; 0 and 112,088,065 shares issued and outstanding as of september 30, 2021 and december 31, 2020, respectively; liquidation preference of 0 and 450,850 as of september 30, 2021 and december 31, 2020, respectively | ||||||||||||||
| common stock (class a and b), 0.00001 par value; 2,000,000,000 (class a 1,989,032,117, class b 10,967,883) and 188,400,000 shares authorized as of september 30, 2021 and december 31, 2020, respectively; 168,634,959 (class a 159,167,076, class b 9,467,883) and 22,314,685 shares issued and outstanding as of september 30, 2021 and december 31, 2020, respectively | 2,000 | |||||||||||||
| total liabilities, convertible preferred stock and stockholders’ equity | 658,606,000 | 698,590,000 | ||||||||||||
| convertible preferred stock (series a, a-1, b, c, and d), 0.00001 par value; 200,000,000 and 121,434,713 shares authorized as of june 30, 2021 and december 31, 2020, respectively; 0 and 112,088,065 shares issued and outstanding as of june 30, 2021 and december 31, 2020, respectively; liquidation preference of 0 and 450,850 as of june 30, 2021 and december 31, 2020, respectively | ||||||||||||||
| common stock (class a and b), 0.00001 par value; 2,000,000,000 (class a 1,989,032,117, class b 10,967,883) and 188,400,000 shares authorized as of june 30, 2021 and december 31, 2020, respectively; 168,425,907 (class a 158,958,024, class b 9,467,883) and 22,314,685 shares issued and outstanding as of june 30, 2021 and december 31, 2020, respectively | 2,000 | |||||||||||||
| liabilities, convertible preferred stock and stockholders’ deficit | ||||||||||||||
| convertible preferred stock (series a, a-1, b, c, and d), 0.00001 par value; 121,434,713 shares authorized as of march 31, 2021 and december 31, 2020; 112,088,065 shares issued and outstanding as of march 31, 2021 and december 31, 2020; liquidation preference of 450,850 as of march 31, 2021 and december 31, 2020 | 448,312,000 | |||||||||||||
| stockholders’ deficit | ||||||||||||||
| total stockholders’ deficit | -233,031,000 | |||||||||||||
| total liabilities, convertible preferred stock and stockholders’ deficit | 271,943,000 |
We provide you with 20 years of balance sheets for Recursion Pharmaceuticals . stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as asset and liabilities, payables and receivables, long debts and short debts, cash and inventories, expenses and profits. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Recursion Pharmaceuticals .. Explore the full financial landscape of Recursion Pharmaceuticals . stock with our expertly curated balance sheets.
The information provided in this report about Recursion Pharmaceuticals . stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.